Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Drugs Exp Clin Res ; 27(5-6): 199-208, 2001.
Article in English | MEDLINE | ID: mdl-11951578

ABSTRACT

Ninety-two patients suffering from herpes zoster were enrolled in a double-blind controlled study aimed at evaluating the efficacy and tolerance of the drug neuramide. Neuramide (N) and placebo (P) were administered to patients intramuscularly twice daily for 28 days as follows: group N + N (patients always treated with neuramide); group N + P (patients treated with neuramide for 1 week, then with placebo); group P + N (patients treated with placebo for 1 week, then with neuramide); group P + P (patients always treated with placebo). During the first week, all patients were also treated with standardized doses of acyclovir. The presence and extent of clinical symptoms were evaluated during the first 4 weeks, while the appearance, degree and duration of postherpetic neuralgia were evaluated both during treatment and over a 6-month follow-up period. There were no significant differences between the four groups of patients when subjective parameters (such as pain and paresis at the lesion site) were examined. However, clinical examination at the end of treatment showed that treatment with neuramide was therapeutic. Indeed, the times for recovery and for regeneration of epithelium were significantly shorter when neuramide was administered for 3 weeks of the treatment period. Furthermore, the change from vesicles to crusts was significantly faster in the neuramide group than in the placebo group. Postherpetic neuritis occurred in the first months of follow-up. However, in groups N + P and P + P, the symptoms lasted throughout the 6-month observation period, while in the other groups this period was shorter. Indeed, there were significant differences (p < 0.05) in terms of the above complications between the following groups: N + N and N + P; N + N and P + P; N + P and P + N; P + N and P + P. No significant differences were observed between the N + N and P + N, or N + P and P + P groups. Taken together, these data demonstrate that neuramide treatment for at least 3 weeks significantly reduces the risk of postherpetic neuritis development.


Subject(s)
Antimicrobial Cationic Peptides/therapeutic use , Antiviral Agents/therapeutic use , Herpes Zoster/drug therapy , Neuritis/drug therapy , Acyclovir/therapeutic use , Adult , Aged , Aged, 80 and over , Antimicrobial Cationic Peptides/adverse effects , Antiviral Agents/adverse effects , Double-Blind Method , Female , Follow-Up Studies , Herpes Zoster/complications , Herpes Zoster/pathology , Humans , Male , Middle Aged , Neuritis/etiology , Neuritis/prevention & control
2.
Contact Dermatitis ; 34(5): 354-8, 1996 May.
Article in English | MEDLINE | ID: mdl-8807230

ABSTRACT

Numerous studies have focused attention on the influence of various biological and environmental factors on contact hypersensitivity. In order to evaluate the persistence and/or modification of allergic contact sensitivity to a number of common contact sensitizers, the same standardized patch tests were repeated on 174 subjects with contact sensitivity after a time lapse of 5 years (1987-1992). In 18.4% of the cases, 1 or more sensitivities were lost; 28.7% of the patients had a higher number of positive patch tests after 5 years, while the remaining 52.9% of the patients showed no change in the number of positive patch tests. In 88%, the positive allergens were unchanged, whereas in the remaining 12% of the subjects, they showed 1 or more variations. The association between the allergens most often positive was calculated for both the 1st and the 2nd patch test results. Moreover, to evaluate the frequency of an allergen's positivity, we studied the disappearance of old sensitivities and the appearance of new sensitivities by the McNemar test. Cobalt chloride was the only allergen with a significant frequency of new positivities over the period of observation (p < 0.01). Logistic regression analysis was performed to evaluate the possible influence of positive tests to other allergens, and of some clinical findings associated with contact dermatitis, on the sensitivity to cobalt chloride in 1987 and in 1992.


Subject(s)
Dermatitis, Allergic Contact/diagnosis , Patch Tests , Adult , Aged , Allergens , Female , Follow-Up Studies , Humans , Logistic Models , Male , Middle Aged , Odds Ratio
4.
Contact Dermatitis ; 26(5): 307-10, 1992 May.
Article in English | MEDLINE | ID: mdl-1395592

ABSTRACT

The results of 7 months of patch testing with a standard series of 26 allergens in 323 children with eczematous conditions or itching palmoplantar psoriasis under the age of 14 years are reported. 114 (35.3%) of the children had 1 or more positive reactions to this standard series. 28 children (8.7%) were polysensitive. On the basis of personal history, additional series of allergens and/or specific allergens were also tested. 61.7% (90/146) of positive reactions were considered relevant to the current dermatitis. Metals, medicaments, preservatives or fragrances, and shoe components were the major sources of contact sensitization. It is suggested that patch testing be done more frequently in evaluating dermatitis in children.


Subject(s)
Dermatitis, Contact/diagnosis , Dermatitis/diagnosis , Adolescent , Child , Child, Preschool , Dermatitis/etiology , Dermatitis, Atopic/diagnosis , Dermatitis, Atopic/etiology , Dermatitis, Contact/etiology , Female , Humans , Infant , Italy , Male , Multicenter Studies as Topic , Patch Tests , Prevalence
5.
G Ital Dermatol Venereol ; 124(1-2): 51-3, 1989.
Article in Italian | MEDLINE | ID: mdl-2527810

ABSTRACT

Two cases of clubbing of fingers and toes with congenital keratosis palmo-plantaris are reported. After a quick review of the factors involved in clubbing and keratoderma palmaris et plantaris, the inheritance tendency is discussed.


Subject(s)
Keratoderma, Palmoplantar/complications , Osteoarthropathy, Secondary Hypertrophic/complications , Adult , Humans , Keratoderma, Palmoplantar/genetics , Male , Osteoarthropathy, Secondary Hypertrophic/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...